BTIG raised the firm’s price target on Progyny to $50 from $45 and keeps a Buy rating on the shares. Larger than expected decline in utilization resulted in slower fertility revenue growth, though the he shift in treatment mix could be short-lived and overall growth expected for the full-year 2024E remains strong, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PGNY:
- Progyny, Inc. Announces Fourth Quarter 2023 Results
- Progyny initiated with an Outperform at Leerink
- PGNY Earnings this Week: How Will it Perform?
- Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results Report
- Vistia Health selects Progyny as fertility, family building benefits provider
